Skip to main content
Matthias Lee, MD, Pulmonology, Seattle, WA

MatthiasKLeeMD

Pulmonology Seattle, WA

Physician

Are you Dr. Lee?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
    You already have 29 invites waiting!
  • Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

  • Office

    1100 9th Ave
    Seattle, WA 98101
    Phone+1 206-223-6600

Summary

  • Dr. Matthias Lee, MD is a pulmonologist in Seattle, Washington. He is currently licensed to practice medicine in Washington, Connecticut, and California. He is affiliated with Virginia Mason Medical Center.

Education & Training

  • Stanford Health Care-Sponsored Stanford University
    Stanford Health Care-Sponsored Stanford UniversityResidency, Psychiatry, 1996 - 2000
  • Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo
    Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 1996

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1997 - Present
  • WA State Medical License
    WA State Medical License 2003 - 2025
  • CT State Medical License
    CT State Medical License 2002 - 2004
  • American Board of Psychiatry and Neurology Psychiatry
  • American Board of Psychiatry and Neurology Sleep Medicine

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification HealthSentry EHR, Cerner Corporation, 2013

Publications & Presentations

PubMed

Press Mentions

  • Study Shows Use of Smartphone App Associated with Lower Hospital Readmission Rates for Heart Attack Survivors
    Study Shows Use of Smartphone App Associated with Lower Hospital Readmission Rates for Heart Attack SurvivorsSeptember 21st, 2021
  • CV Drugs Not Linked to Poor Outcomes in Patients at High Risk for COVID-19
    CV Drugs Not Linked to Poor Outcomes in Patients at High Risk for COVID-19August 9th, 2021